Osteoarthritis knee pain
TLC, a clinical-stage specialty pharmaceutical company, announced that the first patient has been enrolled in EXCELLENCE, the phase III pivotal clinical trial for TLC599 in patients with osteoarthritis knee pain. TLC599 is a non-opioid, proprietary BioSeizer sustained release formulation of dexamethasone sodium phosphate (DSP) intended to manage OA pain for up to six months.
Voor andere berichten over phase III berichten, KLIK HIER!
